Anti-Seizure and Anti-Epileptogenic Effects of New, Selective mTor Inhibitors
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
PRE
P1
P2
P3
Pipeline Type
New Drugs in Development
Phase Of Development
Preclinical
Sponsors and Collaborators
PIQUR Therapeutics, Wolfgang Loescher, Epilepsy Foundation (EF)
Mechanism of Action
mTOr
Mechanism Description
mTOR inhibitors
Populations Tested In
Tuberous Sclorosis rodent models
Other Resources
Special FDA Designation
Nonprofit or Government Support
Nonprofit
Nonprofit or Government Support Description
Epilepsy Foundation - NTCG 2017
Previous Presentations
Presented at meetings (latest date) (Pipeline, AEDD; AES, Eilat, etc)
N/A
Location of Clinical Trials
N/A
Clinical Trial link